PBH

Over the past six months, Prestige Consumer Healthcare's stock price has decreased by 33.61%. Key events impacting the stock include decreased revenue in Fiscal Q1 2026 due to supply constraints for Clear Eyes, surpassing sales and earnings expectations in Fiscal Q2 2026, the acquisition of Pillar5 Pharma, reporting revenue of $283.4 million in Fiscal Q3 2026, the agreement to acquire Breathe Right® and other brands from Foundation Consumer Healthcare for $1.045 billion, price target adjustments by Oppenheimer, and share repurchases.